ACTOS

This brand name is authorized in United States. It is also authorized in Australia, Austria, Croatia, Estonia, Hong Kong SAR China, Ireland, Israel, Italy, Japan, Lithuania, Netherlands, Poland, Romania, Singapore, Spain, Tunisia, Turkey, UK.

Active ingredients

The drug ACTOS contains one active pharmaceutical ingredient (API):

1	Pioglitazone UNII JQT35NPK6C - PIOGLITAZONE HYDROCHLORIDE
	Pioglitazone effects may be mediated by a reduction of insulin resistance. Pioglitazone appears to act via activation of specific nuclear receptors (peroxisome proliferator activated receptor gamma) leading to increased insulin sensitivity of liver, fat and skeletal muscle cells in animals. Treatment with pioglitazone has been shown to reduce hepatic glucose output and to increase peripheral glucose disposal in the case of insulin resistance.
	Read more about Pioglitazone

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ACTOS Tablet	MPI, US: SPL/PLR	FDA, National Drug Code (US)
ACTOS Tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
A10BG03	Pioglitazone	A Alimentary tract and metabolism → A10 Drugs used in diabetes → A10B Blood glucose lowering drugs, excl. insulins → A10BG Thiazolidinediones
Discover more medicines within A10BG03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	8694N, 8695P, 8696Q
EE	Ravimiamet	1013566, 1013577, 1013588, 1209372, 1209383, 1209394, 1209406, 1209417, 1209428, 1209439, 1212411, 1212422, 1212433, 1212444, 1212455, 1212466, 1212477, 1212488, 1212499, 1212501, 1212512, 1212523, 1212534, 1212545, 1494402, 1494413, 1494424, 1494435, 1494446, 1494457
ES	Centro de información online de medicamentos de la AEMPS	00150001, 00150004, 00150004IP, 00150009, 00150010, 00150010IP
GB	Medicines & Healthcare Products Regulatory Agency	140403, 140405, 161338, 175725, 175728, 178953, 180500, 198640, 20095, 20096, 374281, 374283, 374285, 51997
HK	Department of Health Drug Office	47882, 47884
IE	Health Products Regulatory Authority	10330, 10378, 10506, 10568, 10594, 10609, 10661, 10756, 10761, 10797, 10798, 15530, 15590
IL	מִשְׂרַד הַבְּרִיאוּת	7091, 7092, 7093
IT	Agenzia del Farmaco	034946018, 034946044, 034946121
JP	医薬品医療機器総合機構	3969007F1024, 3969007F2020, 3969007F3027, 3969007F4023
LT	Valstybinė vaistų kontrolės tarnyba	1004071, 1004363, 1004508, 1026399, 1026400, 1026401, 1026402, 1026403, 1026404, 1026405, 1026406, 1026407, 1026408, 1026409, 1026410, 1026411, 1026412, 1026413, 1026414, 1026415, 1026416, 1026417, 1026418, 1026419, 1063617, 1063618, 1063619, 1063620, 1063621, 1063622
NL	Z-Index G-Standaard, PRK	84247, 84255
PL	Rejestru Produktów Leczniczych	100308456, 100308462, 100308479
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W08069001, W08069002, W08069003, W08069004, W08069005, W08069006, W08069007, W08069008, W08070001, W08070003, W08070004, W08070005, W08070006, W08070007, W08070008, W08070009, W08071001, W08071002, W08071003, W08071004, W08071005, W08071006, W08071007, W08071008
SG	Health Sciences Authority	12441P, 12442P
TN	Direction de la Pharmacie et du Médicament	5063311, 5063312
TR	İlaç ve Tıbbi Cihaz Kurumu	8682758010016, 8682758010023
US	FDA, National Drug Code	64764-151, 64764-301, 64764-451